Median maximum reversal in evaluable
patients was 100% in first 4 hours†
Most patients achieved complete reversal
as measured by ECT (82%), or dTT (99%)‡
*RE-VERSE AD included data for 503 patients: 301 patients with serious bleeding (Group A) and 202 requiring an urgent procedure (Group B).
†Based on determination for dTT or ECT.
‡In a limited number of patients, elevated coagulation parameters (eg, aPTT or ECT) have been observed 12-24 hours post-dose.
§Accurate as of 01/03/20, based on the current information provided to Boehringer Ingelheim Pharmaceuticals, Inc. The company cannot guarantee the availability of PRAXBIND at all facilities in every state.
References: 1. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377(5):431-441; 1-13 [suppl appendix]. 2. PRAXBIND [Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 3. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
Praxbind® (idarucizumab) is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:
CL-PB-100001 April 2018
Please click here for full Prescribing Information for PRAXBIND.